The Benefits of
cGPMAX™

Life is good when you're healthy.

PATENTED in 30+ countries

30+ YEARS of scientific studies

WORLD first discovery

What is cGP and why is it important?

cGP (Cyclic Glycine-Proline) is a key molecule in your body whose primary role is to normalises the functioning of a life-supporting hormone called Insulin-like Growth Factor 1 (IGF-1).

IGF-1 is responsible for making new blood vessels, in particular, capillaries - the smallest blood vessels in our body that transport nutrients to our main organs and remove wastes, thus keeping our body and brain functioning as nature intended. cGP regulates the IGF-1 to keep it functioning at its best for good health.

As we age our IGF-1 function naturally declines or can occur earlier because of poor lifestyle, stress, or illness. Unfortunately, our body’s ability to naturally produce cGP also slows leaving us vulnerable to poor health outcomes as we age.

As the body’s blood flow is the essence of human life it is important to maintain sufficient cGP levels as we age to ensure optimal functioning of our brain and body.

cGPMax™ safely delivers a daily dose of natural cGP that is scientifically shown to replenish and maintain cGP levels in our body essential to living a full, active and productive life as we age.

In other words…

A good analogy is to imagine the blood vessels in your body are roads in a city, and the IGF-1 is responsible for road maintenance.

As the city grows over time and the roads have constant use, the original roads will not last, they will deteriorate until the cars can no longer use them. Unfortunately, as we age our IGF -1 levels drop so IGF-1 just doesn’t do any road maintenance or doesn’t build new roads.

In addition to ageing, when a person is young and a natural disaster strikes the body, (for example caused by injury or stress), there is an increased use of the body’s roading system. This causes a greater need for road maintenance.

This is where the cGP becomes the hero. The cGP acts like a superfood for the IGF-1 and the more cGP you put into your body, the faster and more efficient the IGF-1 is and the better your body’s roading system.

How cGP powers your brain

The brain plays an important role in our overall health. It nomalises every process in our body including our thoughts, memory, emotions, senses, movement and the functioning of all our organs.

Unfortunately, our brain is most affected when our bodies are low in cGP, leaving us vulnerable to a whole range of poor health outcomes. Of all the nutrients we put into our body, the brain requires the most, although it only accounts for 1-2% of our body weight it consumes a whopping 25-30% of nutrients.

cGPMAX™ Brain Health has been formulated to increase the supply of nutrients to the brain, supporting brain health and function as we age. It can also support energy levels, mental clarity, focus and sleep and balance stress and mood.

cGP Research

Do you want to find out more about the 30 years of research that has gone into developing cGPMAX™ ?

A Selected List of cGPMAX™ Scientific Papers

2021 Singh-Mallah G, Ardalan M, Singh K, Kang D, McMahon C, Mallard C and Guan J. Administration of cyclic glycine-proline during infancy improves adult spatial memory, astrocyte plasticity, vascularization and GluR-1 expression in rats. Nutritional Neuroscience. August 2021
2021 Kang D, Waldvogel H, Fan D, Wang A, Faull R, Curtis M, Shorten P and Guan J. The autocrine regulation in human brain of Alzheimer’s diseases. Accepted with revision in Psychoneuroendocrinology
2020 Fan D, Pitcher T, Dalrymple-Alford J, MacAskill M, Anderson T and Guan J. Plasma cGP/IGF-1 molar ratio is associated with cognitive status of Parkinson disease. Alzheimer’s Dement. 2020;1–10.
2019 Li FX, Liu K, Gray C, Harris P, Reynolds C, Vickers M and Guan J. Cyclic glycine-proline normalizes systolic blood pressure in high-fat diet-induced obese male rats. Nutrition, Metabolism & Cardiovascular Diseases. 30: 339-346
2019 Li FX, Liu K, Wang A, Harris P, Vickers M and Guan J. Cyclic Glycine-Proline Administration Normalizes High-Fat Diet-Induced Synaptic Expressions in Obese Rats. Neuropeptides 76, 101935, 10.1016/j.npep.2019.05.006
2019 Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J. Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. Annals of Clinical Translational Neurology 2019;0
2018 Fan D, Alamri Y, Liu K, MacAskill M, Harris P, Brimble M, et al. Supplementation of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to Improve Insulin-Like Growth Factor-1 Function. Nutrients 2018;10:714. doi:10.3390/nu10060714.
2018 Alamri Y, The use of dietary supplements and perceived quality of life in patients with Parkinson's disease. J Clin Neuroscience 56: 137-136
2018 GUAN J, SINGH-MALLAH G, LIU K, SHORTEN P, THOMPSON J, MITCHELL E, TAYLOR R, HARRIS P, BRIMBLE M, THORSTENSEN E AND MURPHY R. The role for autocrine regulation of IGF-1 in pregnancy related obesity, a potential biomarker for weight changes. Journal of Biological Regulators and Homeostatic agents 32(3): 11-25
2017 SINGH-MALLAH G, MCMAHON CD, GUAN J and SINGH K Cyclic-glycine-proline promotes post-lactational involution in mammary glands of rats through inhibiting IGF 1 function. Journal of Cellular Physiology 232 (12) 3369-3383doi: 10.1002/jcp.25782
2016 SINGH-MALLAH G, SINGH K, MCMAHON CD, HARRIS P, BRIMBLE MA and GUAN J, Maternal-infantile transfer following oral administration of cyclic-glycine-proline in lactating rats and its effect on improving memory in the offspring Endocrinology 157(8):3130-9
2017 YANG P, WALDVOGEL H, Scott E, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Endothelial degeneration of Parkinson disease is related to alpha-synuclein aggregation. Journal of Alzheimer’s Disease & Parkinsonism 7: 370. doi: 10.4172/2161-0460.1000370
2017 YANG P, WALDVOGEL H, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Vascular remodelling is impaired in Parkinson’s diseases, Journal of Alzheimer’s Disease & Parkinsonism 7: 313. doi: 10.4172/2161-0460.1000313
2015 Yang P, Pavlovic D, Richard Faull, Mike Dragunow Beth Synek, Clinton Turner Henry Waldvogel and Guan J, String vessel formation is increased in the brain of Parkinson disease. J of Parkinson Diseases. 5 (2015) 821–8362015
2015 GUAN J, HARRIS P, BRIMBLE M, LEI Y, LU J, YANG Y AND J GUNN A, The role for IGF-1 derived small neuropeptides as a therapeutic target for neurological disorders. Expert Opinion on Therapeutic Targets. Invited review 2015 Feb 5:1-9
2015 PHILLIPS GMA, SHORTEN PR, WAKE GC AND GUAN J, Dynamical modelling of the effect of insulin-like growth factor -1 on human cell growth. Mathematical Bioscience Journal 2015 Jan; 259:43-54.
2014 GUAN J, GLUCKMAN PD, YANG PZ, KRISSANSEN G, SUN K, ZHOU Y, WEN JY, SHORTEN P, WAKE G, MCMAHON CD, THOMAS MF, PHILIP G, CHEN W, S MOON, A REN AND LIU DX, Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1 Scientific Report, 4, 4388
2014 MATHAI S, GUNN AJ, BRIMBLE MA, HARRIS PW AND GUAN J. Neuroprotection with Glycin-2methyl-Proline-Glutamate (G-2mPE) after hypoxic-ischemic brain injury in adult rats. Journal of Experimental Stroke Translational Medicine 6: 1-112013
2013 GUAN J, MATAI S, LIANG HP AND GUNN JA Insulin-like growth factor-1 and its derivatives: Potential pharmaceutical application for treating neurological conditions. Recent Patents on CNS drug discovery 2013 8(2) 142-168
2013 Guan J, Pavlovic D, Darkie N, Waldvigel H, Green C and Nicholson L. Vascular degeneration of Parkinson Disease. Brain Pathology 23(2) 154-164 (impact factor 4.7 doi: 10.1111/j.1750-3639.2012628)
2012 MATHAI S, GUNN AJ, BACKHAUS A AND GUAN J Window of opportunity for neuroprotection with an antioxidant, Allene Oxide Synthase, after hypoxia-ischemia in adult male rats, Journal of Neuroscience and Therapeutics 18(11):887-94
2012 ZHANG R, KADAR T, SIRIMANNE E, MACGIBBON A AND GUAN J Age-related memory decline in rats is associated with vascular and microglial degeneration, Behavioural Brain Research 1;235(2):210-7
2010 GUAN J, ZHANG R, L DALE GANDAR AND VICKERS M. NNZ-2591, A novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behavioural Brain Research 210, 221-228.
2009 GUAN J AND GLUCKMAN P. Endogenous small neuropeptides and their analogues: a novel strategy for the development of pharmaceuticals for neurological conditions, invited review by British Journal of Pharmacology 157, 881-891
2009 SHAPIRA S, MATHAI S, ZHANG R AND GUAN J Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsphere induced embolic damage in young adult and aged rats. Neuroscience Letter 454 (1) 53-57
2009 KRISHNAMURTHI, R V M., KIM A H., MATHAI S. RONG ZHANG AND GUAN J. Delayed treatment with a novel diketopiperazine improves motor function after 6-OHDA lesion in rats. British Journal of Pharmacology 156, 662-672.
2008 JACOBSON L, ZHANG R, ELLIFFE D, CHEN C, MATHAI S, MCCARTHY D, WALDVOGE H AND GUAN J. Co-relation of cellular/vascular changes and spatial memory during aging in rats Experimental Gerontology 43, 928-938
2007 GUAN J, MATHAI S, HARRIS P, BRIMBLE M, WEN JY ZHANG R and GLUCKMAN P Peripheral administration of a novel diketopiperazine, NNZ 2591 prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacolocy 53: 749-762
2007 SVEDIN P, GUAN J*(co-responding author), MATHAI S, ZHANG R, WANG XY, HAGBERG H AND MALLARD C Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat. Developmental neuroscience 29: 393-402
2005 BAKER A M, BATCHELOR D C, THOMAS G B, CLARK R G, RAFIEE M, LIN H AND GUAN J Central penetration and the stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 39(2) 81-87
2004 GUAN J, THOMAS G B, LIN H, MATAI S, BACHELOR D C, GEORGE S, FERNANDEZ J AND GLUCKMAN PD Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor –1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology Vol 47 (6): 892-903
2004 KRISHNAMURTHI R, STOTT S, MAINGAY M, FAULL RLM, MCCARTHY D, GLUCKMAN PD AND GUAN J. N-terminal tripeptide of insulin-like growth factor –1 (GPE) improves functional deficits after 6-OHDA lesion in rats. NeuroReport 15(10); 1601-1604
2003 GUAN J, BENNET L PD GLUCKMAN AND GUNN AJ, Insulin-like growth factor-1 and the ischemic brain. Progress in Neurology 70 (6), 443-462
2000 GUAN J., KRISHNAMURTHI, R., WALDVOGEL, H.J., FAULL, R.L.M., CLARK, R. AND GLUCKMAN, P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Research 859 (2) 286-292,
1999, GUAN J, WALDVOGEL H, FAULL R, GLUCKMAN P AND WILLIAMS C The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 89: 649-659

Tracking your progress

As with anything you take, the noticeable effects of cGPMAX™ Brain Health will vary from person to person. Some customers report they notice changes within a week and others report a more subtle change. Some people struggle to define exactly how it affects them beyond an overall feeling of increased energy and wellness.

To help you track how cGPMAX™ Brain Health has benefited your health and wellbeing you can complete our health questionnaire available on our website. We recommend completing it before you start taking cGPMAX™ Brain Health and again after 3 months.

Download PDF